In other words take Dr. Tefferi and the MAYO out of the equation and what are you left with?
Maybe we should just scrap Scarlet altogether and pay Tefferi the $million. It wouldn't be hard to vote Chippy off the gerny considering he hardly owns any shares.
...my reply keeps getting removed...so won't mention the drugs involved but there is no scientific proof that carrot juice cures cancer. Lots of anecdotal evidence but much of it confused with adjuvant therapy. I've witnessed cancer patients turn color and develop hives with naturopathic therapies which did not work.
He does have a point when the SP tanks by 70% after the FDA hold announcement catching the CEO off guard. I had reservations after Scarlet's feeble response back at the Jan CC in San Fran's Drake hotel; he seemed perplexed about how to move fwd wrt to clinical models endpoints & had no plans to fast track the drug but after several months without FDA alerts felt the company had everything on track awaiting latest updated data and moving fwd with a larger phase 2 cohort multi center study.. We have not been updated yet with this or the latest clinical results from the MAYO, the only on going trial on 'partial' hold restrictions. Scarlet said last CC perhaps at the ASH which is in Dec. None of this instills shareholder confidence and frankly for a $1mil/ year salary he seems rather aloof to shareholders equity. Perhaps he should be compensated in shares rather than our hard 'lost' cash investment. Just sayin.
Many of today's modern drugs are based on natural compounds. High input screening bio labs test tens of thousands of compounds daily for any medical potential. Once isolated they are concentrated, tweaked and tested for efficacy. To rely strictly on natural remedies for oncology today you may as well get treatment in Borneo. I still chew on willow bark to treat headaches but then I'm a beaver.
Happens every easter...should have a resurrection by Monday. That or the easter bunny pulled out of OHRP#$%$.
another 2 Robert Marcin posts together when he was a more optimistic fan
Scutify April 10th, 2014: "one would believe bottom is in if deal serviced new institutional investors who need to fill out positions. interim data should be released by back half of May, and that's the money report. if results progressing well, stock should claw back then surge."
Scutify April 13th, 2014: "remains my largest position, despite having called the biotech space a bubble. I continue to believe that the results will show an 75%+ reduction in shots with many patients being treated by squalamine alone. I still think its a billion $$$ drug. Interim results cannot come soon enough, hopefully in the next 4-5 weeks. I remain an ohr-fan, despite the disappointment of the equity deal last week."
The only gap I see is the one between Marcin's ears. Last open GAP OHRP had was a downward one Apr-08-2014 11.84 to 10.57 reflecting the low ball insider secondary.
The SP today closed at the 200DMA as you say but it did break below it's main trend line support of $10 which is 'still' intact. The candle formed was an inverted hammer which is very bullish so short of Putin playing the mean old bear with bad bladder leakage, we should see some buying strength that would get us back up to our previous support range above $10.
If not it was a certainly an experience on the Mensa board.
...and the patients awaiting treatment for the expanded Imet MF trials now on hold with grade 3 MF are probably dying or dead so what's your point hairy?
By keeping SP below $2+ calls expire worthless no payout by issuer and puts are in the money but fewer issues.
Well at least you didn't buy in at the high of $54 in 2000. It was followed buy a dble top of $32 and continued downward to $1.07 last March. If that didn't make you sell in 14 yrs why would $1.98?
"The Phase 1 trial is a two-month, open-label study in approximately 30 patients at 15 to 20 clinical sites around the United States. The trial is designed to assess the safety and tolerability of topical ocular PAN-90806 at three dosage strengths in patients with active, subfoveal choroidal neovascularization associated with neovascular AMD. PanOptica expects data readout by the end of 2014"
They should have phase 1 results about the same time as Squalamines's phase 2 are due.
FDA just approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes. Tanzeum will carry a warning on its label that tumors of the thyroid gland were observed in rodent studies. I guess that's okay by the FDA
His career was cut short when his parents left Burbank for Philly. Larry Mondello for prez! Maybe we should start a petition?
I agree he maybe 'overcompensated' but name me one American CEO that isn't...most CEO's average $11.5mil/annually which is 331x what the average American worker makes, 750 x the lowest paid workers. And yet they all balk at raising the min. wage. Unless you're a beaver eating wood fiber that ain't any sustainable system.
I just hate being in any equity with such thin liquidity when macro market sentiment has become so bearish. Leaves any equity vulnerable to shorting, naked or legit and HFT take downs.
....and we all know naked shorts don't cover cause they never really existed in the first place. My broker doesn't allow shorting this equity so it must be mainly all larger hedge funds playing the SP.